Biotechnology

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn’s and Colitis Organization (ECCO)

February 13, 2024 2:50 AM

PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that four scientific abstracts on its lead drug candidate, obefazimod for the treatment of...

Read more

Imagene Increases Accessibility of Rapid AI-Based Biomarker Profiling Through Integration With Sectra

February 12, 2024 9:00 AM

ImageneOI is the first NSCLC genomic profiling AI tool on the Sectra Amplifier Marketplace. TEL AVIV, ISRAEL / ACCESSWIRE / February 12, 2024 / Imagene, a pioneer in AI-based precision oncology, today announced the integration of its groundbreaking AI-based biomarker profiling platform, ImageneOITM, with international medical imaging IT company Sectra and their digital pathology solution. Healthcare providers around the world using the Sectra...

Read more

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

February 9, 2024 4:15 PM

TORONTO, ON / ACCESSWIRE / February 9, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three months ended December 31, 2023 and provided an update on its business. During the first fiscal quarter, the company secured funding of up to C$23 million from the Canadian government toward the...

Read more

MRES: M2Biome 2023 Year-End Review and 2024 Looking Forward

February 9, 2024 9:30 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / February 9, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to announce the following updates for its M2Biome division: The M2Biome division relates to...

Read more

Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan

February 9, 2024 2:20 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / February 9, 2024 / Vicore Pharma Holding (STO:VICO) C21 is a potentially transformative therapy for the treatment of idiopathic pulmonary fibrosis (IPF) Vicore to receive USD 10 million upfront and is entitled to up to USD 275 million in milestones in addition to tiered royalty payments Nippon Shinyaku has been granted exclusive rights to and will be responsible for development of C21 in Japan Vicore retains...

Read more

BioInvent to Evaluate BI-1206 in Combination with Rituximab and Calquence

February 9, 2024 2:20 AM

LUND, SWEDEN / ACCESSWIRE / February 9, 2024 / BioInvent International (STO:BINV) Clinical supply agreement with AstraZeneca to support Phase 1/2a BI-1206 combination study BI-1206 to be evaluated in combination with Calquence® and rituximab in Phase 1/2a trial in non-Hodgkin's lymphoma The ongoing rituximab combination trial will be expanded to include the triplet arm Lund, Sweden - February 9, 2024 - BioInvent International AB ("BioInvent")...

Read more

Hemogenyx Pharmaceuticals PLC Announces FDA Consents to Phase I Trials of HEMO-CAR-T

February 9, 2024 2:00 AM

FDA Consents to Phase I Trials of HEMO-CAR-T LONDON, UK / ACCESSWIRE / February 9, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has been informed by the U.S. Federal Food and Drug Administration ("FDA") that it has lifted the clinical hold on the Investigational New Drug (IND) application for HEMO-CAR-T for the treatment of acute myeloid leukemia ("AML"). The FDA confirmed that the Company had addressed all...

Read more

Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder Meeting

February 8, 2024 4:00 PM

KELOWNA, BC / ACCESSWIRE / February 8, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that further to its press releases of December 11, 2023 and January 26, 2024, Tryp has obtained an interim order (the "Interim...

Read more

AmplifyBio CEO J. Kelly Ganjei Discusses Solutions for Reducing Costs and Risk in Advanced Therapy Manufacturing During Fireside Chat at Advanced Therapies Week

February 8, 2024 7:00 AM

NEW ALBANY, OH / ACCESSWIRE / February 8, 2024 / J. Kelly Ganjei, CEO of AmplifyBio, recently participated in a fireside chat panel at Advanced Therapies Week, a conference event in Miami hosted by the Phacilitate event group that brings together thought leaders in cell and gene therapy development for education, collaboration, and networking opportunities, where he shared insights into the intricacies of advanced therapy manufacturing, drawing...

Read more

TuHURA Biosciences, Inc. Appoints Dennis Yamashita, Ph.D., as Chief Scientific Officer and Head of Discovery Research and Early Development

February 7, 2024 10:00 AM

Brings over 30 years of experience in R&D drug discovery and development with a proven track record, including co-inventing Olinvyk (oliceridine), an FDA-approved Mu opioid G-protein biased ligand for treating post-surgical pain Dr. Yamashita to focus on advancing the Company's novel personalized cancer vaccines to overcome tumor resistance to immunotherapies like checkpoint inhibitors and first-in-class bi-functional antibody drug conjugates...

Read more

Phoreus Biotech Appoints David Schaefer as CEO to Lead Development of Innovative Drug Delivery Nanocarriers

February 7, 2024 8:00 AM

OLATHE, KS / ACCESSWIRE / February 7, 2024 / Phoreus Biotech, an innovator in peptide nanocarriers for drug and vaccine delivery, is proud to announce the appointment of David Schaefer as its new Chief Executive Officer. With more than 25 years of experience in commercial healthcare management, biotechnology, and strategic development, Schaefer brings a wealth of knowledge and expertise to the company. "Phoreus Biotech is at the cutting edge of...

Read more

New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine

February 6, 2024 10:00 AM

Researchers at the BioMed X Institute and the Universitätsmedizin Mannheim just published the results of their collaboration around a new neoepitope vaccine in diffuse midline glioma in Science Advances. HEIDELBERG, GERMANY / ACCESSWIRE / February 6, 2024 / BioMed X and the Universitätsmedizin Mannheim announced today the publication of two manuscripts in the field of cancer immunology in the journal Science Advances. The work is based on a...

Read more

Cantabio Pharmaceuticals Awarded Major Grant from The Michael J. Fox Foundation for the Development of a Novel DJ-1 Protein Replacement Therapy for the Treatment of Parkinson’s Disease

February 6, 2024 10:00 AM

Grant enables the further development of Cantabio's innovative DJ-1 replacement therapy, which have high therapeutic potential in both disease-modifying and preventive contexts for the treatment of Parkinson's disease. SAN MATEO, CA / ACCESSWIRE / February 6, 2024 / Cantabio Pharmaceuticals, Inc. ("Cantabio" or the "Company"), a preclinical stage pharmaceutical company developing disease-modifying therapeutics and diagnostics for Parkinson's...

Read more

Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates

February 6, 2024 7:00 AM

NORTH PALM BEACH, FL and NEW YORK, NY / ACCESSWIRE / February 6, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies for the treatment of various cancers and viral infections, announced today it has entered into a research collaboration agreement with Manhattan BioSolutions, Inc. (Manhattan Bio), an emerging biotech company focused on...

Read more

Roquefort Therapeutics PLC Announces Operations Update

February 6, 2024 2:00 AM

LONDON, UK / ACCESSWIRE / February 6, 2024 / Roquefort Therapeutics (LSE:ROQ)(OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, provides an update on its pre-clinical drug development programs, Randox licencing agreement and out-licencing discussions. Pre-Clinical Drug Development Programs Further to the Company's announcement on 6 November 2023,...

Read more

MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value

February 5, 2024 5:15 PM

Tafasitamab sold to Incyte Novartis to launch a voluntary public takeover offer for all MorphoSys shares at a price of € 68.00 per share in cash Shareholders benefit from attractive premium of 94 percent to the one-month volume weighted average price before January 25, 2024 Novartis provides ample resources to maximize and accelerate pelabresib's potential on a global scale MorphoSys' Management Board and Supervisory Board unanimously support...

Read more

ARRALYZE(R) Launches CellShepherd(R): A Fully Autonomous Single-Cell Platform For Real-Time Monitoring Of Functional Assays

February 5, 2024 8:30 AM

GARBSEN, GERMANY / ACCESSWIRE / February 5, 2024 / ARRALYZE®, the Life Science arm of LPKF Laser & Electronics SE, proudly announces the commercial availability of the CellShepherd®. After a successful beta-testing phase in 2023, this groundbreaking platform is now ready to revolutionize cell-based research and development across biomedical and various life science fields. CellShepherd®: Redefining Single-Cell Analysis CellShepherd®, developed...

Read more

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

February 5, 2024 8:30 AM

Phase 1 clinical trial dosing of first patient complete; primary objective to assess safety/tolerability and absolute bioavailability of TH104 Phase 1 study expected to be completed in 1Q24 with topline readout in 2Q24 Company fully funded into 2025 with full readouts of Phase 1 and 2 in moderate-to-severe chronic pruritus in PBC expected in 4Q24/1Q25 BRIDGEWATER, NJ / ACCESSWIRE / February 5, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune"...

Read more

WallabyPhenox Boldly Sets New Benchmark in Evidence-Based Medicine With the PROST Trial

February 5, 2024 8:00 AM

PROST Stroke Trial Results Published in JAMA Neurology IRVINE, CA / ACCESSWIRE / February 5, 2024 / WallabyPhenox, a global pioneer in stroke healthcare innovation, has announced the publication of PROST in JAMA Neurology. Visit JAMA Neurology to view the publication. Commenced in 2019, this clinical study marks a significant advancement in the treatment of strokes caused by large vessel occlusion (LVO), a condition contributing to severe...

Read more

Hemogenyx Pharmaceuticals PLC Announces the Approval and Issuance of U.S. Conditioning Patent

February 2, 2024 2:00 AM

Approval and Issuance of U.S. Conditioning Patent LONDON, UK / ACCESSWIRE / February 2, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that a patent application entitledMethod of Eliminating Hematopoietic Stem Cells/Hematopoietic Progenitors (HSC/HP) In A Patient Using Bi-Specific Antibodieshas been allowed to be issued as a patent by the United States Patent and Trademark Office. Dr Vladislav Sandler, CEO & Co-Founder of...

Read more